Search | Clinical Trials Finder

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperdal Consta; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 55 Years
Timeline: Started 2005
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions: Aripiprazole, Risperidone, Modafinil; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
Interventions: Ziprasidone, aripiprazole, quetiapine, or risperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 13 Years to 18 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Interventions: clozapine, risperidone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more

Conditions: Schizophrenia
Interventions: LY2140023, aripiprazole, olanzapine, risperidone; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more

Conditions: Schizophrenia (Recent-onset)
Interventions: paliperidone palmitate, risperidone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 45 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: Paliperidone palmitate Treatment A, Paliperidone palmitate Treatment B; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Cerritos, California • National City, California • San Diego, California + 2 more

Conditions: Schizophrenia
Interventions: RISPERDAL CONSTA, Paliperidone palmitate; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 1,221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 12 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Risperidone, Exposure/ritual prevention therapy (EX/RP), Placebo; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: paliperidone palmitate, oral risperidone; Drug
Lead sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 23
States / cities: Little Rock, Arkansas • Garden Grove, California • San Diego, California + 20 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: quetiapine fumarate, risperidone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,098 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 63
States / cities: Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more

Conditions: Bipolar Disorder
Interventions: Divalproex Sodium, risperidone; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 10 Years to 20 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperidone, Olanzapine, Quetiapine, Aripiprazole; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 28
States / cities: Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more

Conditions: Weight, Body
Interventions: Risperidone, Aripiprazole; Drug
Lead sponsor: Duke University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 37
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more

Conditions: Schizophrenia, Alzheimer's Disease, Dementia
Interventions: Aripiprazole, Olanzapine, Risperidone; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 40 Years and older
Enrollment: 406 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
Interventions: clozapine, risperidone; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 17 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 5
States / cities: Concord, New Hampshire • Lebanon, New Hampshire • Manchester, New Hampshire + 1 more

Conditions: Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions: risperidone (Risperdal); Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 3
States / cities: Tampa, Florida • Cincinnati, Ohio • Dallas, Texas

Conditions: Bipolar Disorder
Interventions: Risperidone oral solution, Valproate Oral Solution, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 7 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 2
States / cities: Cincinnati, Ohio • Milwaukee, Wisconsin

Conditions: Schizophrenia
Interventions: ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more

Conditions: Bipolar Disorder
Interventions: Risperidone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anorexia Nervosa
Interventions: Risperidone, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling; Drug · Behavioral
Lead sponsor: Joseph Blader; NIH
Eligibility: 6 Years to 12 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas

Conditions: Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit/Hyperactivity Disorder (ADHD), Intermittent Explosive Disorder, Impulse-Control Disorders, Adjustment Disorder, Bipolar Disorder, Pervasive Developmental Disorder
Interventions: Risperdal; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 4 Years to 14 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

Risperdal Consta and Health Care Utilization in Patients With Schizophrenia

Antipsychotic Effects on Brain Function in Schizophrenia

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

CLOZAPINE Response in Biotype-1

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

Long-term Antipsychotic Pediatric Safety Trial

Side Effects of Newer Antipsychotics in Older Adults

First Episode Schizophrenia and Cannabis-Related Disorder Study

A Study of Risperidone Monotherapy in Bipolar Anxiety

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania

A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.